glp-1 medullary thyroid cancer GLP1 medications have led to increased risk of in rodents and therefore should not be used in those with a personal or family history of medullary thyroid cancer or MEN2 Currently GLP1s have a warning

Jardiance can cause mild weight loss, but it is usually less significant than with Ozempic

I had been taking steroids as a sticking paster for my eczema

New trends in adverse respiratory events from ASA Closed Claims Project

#getretiredstayretired | Craig Bolanos

Additional common gastrointestinal effects during early treatment include: Diarrhea (affecting 18-24% of patients) usually begins within the early weeks of treatment Constipation (occurring in 16-17% of patients) can develop as gastric motility decreases Vomiting (reported by 8-10% of patients) typically accompanies more severe nausea episodes Abdominal pain or discomfort (affecting 6-10% of patients) often described as cramping or bloating Decreased appetite (experienced by 6-10% of patients) usually noticeable within the first few days Dyspepsia (indigestion) and eructation (belching) additional common digestive symptoms Beyond gastrointestinal symptoms, some patients experience injection site reactions including redness, itching, or mild swelling at the administration site